Kelly Robertson, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 188 Evergreen Rd, Lake Wylie, SC 29710 Phone: 407-690-2056 |
Barbara E. Anslow-myers, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 530 Little Cove Ln, Lake Wylie, SC 29710 Phone: 518-368-5816 Fax: 803-675-0920 |
Ms. Maureen Pilgrim Sell, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4877 Charlotte Hwy, Lake Wylie, SC 29710 Phone: 803-831-9900 |
Lindsay Coleman Romich, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 530 Little Cove Ln, Lake Wylie, SC 29710 Phone: 803-619-4075 Fax: 803-675-0920 |
Melissa Colon Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 624 Altamonte Dr, Lake Wylie, SC 29710 Phone: 787-671-8120 |
Barbara Ellen Anslow-myers Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 530 Little Cove Lane, Lake Wylie, SC 29710 Phone: 518-368-5816 |
Ms. Tanisha Jalene Morrison Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 252 Latitude Ln # 1035923, Lake Wylie, SC 29710 Phone: 803-818-0218 |
News Archive
Exoskeleton leader ReWalk Robotics announced today that the U.S. Food and Drug Administration has cleared the company's ReWalk Personal System for use at home and in the community. ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk.
A recent study led by MedImpact Healthcare Systems, Inc. investigated a pilot Value-Based Benefit Design program to improve adherence to diabetes medications. The study found that a VBBD program that reduced copayments for diabetes medications by 36 percent reduced the number of non-adherent patients by 30 percent.
New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation.
› Verified 4 days ago